VYGR May 2024 7.500 call
| Previous Close | 1.3500 |
| Open | 1.5000 |
| Bid | 1.1500 |
| Ask | 1.6000 |
| Strike | 7.50 |
| Expire Date | 2024-05-17 |
| Day's Range | 1.5000 - 1.6000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 128 |
ZacksAgios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
- Zacks
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
GlobeNewswireVoyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALSLEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven gene th
